Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06217939

Early Intravenous Hydrocortisone in Sepsis

Led by Siriraj Hospital · Updated on 2026-01-07

230

Participants Needed

1

Research Sites

114 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this clinical trial is to compare two timings of steroid treatment in patients with severe infection who develop low blood pressure. The main question it aims to answer is: • Which timing strategy is better between starting steroid treatment very early in the course of severe infection, or waiting until the patient does not respond to medicine that raises blood pressure according to the current guidelines? Participants will receive either early steroid treatment or placebo right after they develop low blood pressure from infection. Both participants and treating doctors will not know which treatment participants received. When blood pressure goal is not reached after a moderate dose of drugs that raise blood pressure, an open-label steroid treatment will be given to participants as indicated in the current guidelines.

CONDITIONS

Official Title

Early Intravenous Hydrocortisone in Sepsis

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age of 18 years or older
  • Suspected or definite sepsis Sepsis is defined by SEPSIS-3 definition as Sequential Organ Failure Assessment (SOFA) score ≥ 2 from baseline with suspected infection.2 Suspected sepsis is defined as patients with suspected infection who meet 2 or more criteria of quick SOFA (altered mentation, respiratory rate ≥ 22/min, systolic blood pressure ≤ 100 mmHg).
  • Hypotension (mean arterial pressure < 65 mmHg)
Not Eligible

You will not qualify if you...

  • Randomization and administration of the study drugs are not able to be executed within 3 hours after the onset of hypotension
  • Causes of shock other than sepsis identified
  • Immunocompromised A patient is considered immunocompromised if one of the following criteria is met: history of human immunodeficiency virus infection or acquired immunodeficiency syndrome, hematologic malignancy, receiving chemotherapy, active cancer receiving chemotherapy, current use of immunosuppressive medication)
  • Hyperglycemic crisis (diabetic ketoacidosis, hyperosmolar hyperglycemic state)
  • Pregnancy
  • Post-cardiac arrest
  • Received etomidate before randomization
  • Systemic corticosteroids indicated for other conditions
  • Received systemic corticosteroids within 4 weeks at any dose
  • Cancer patients who are receiving palliative treatment
  • Do-not-resuscitate order

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Faculty of Medicine Siriraj Hospital, Mahidol University

Bangkoknoi, Bangkok, Thailand, 10700

Actively Recruiting

Loading map...

Research Team

W

Wasin Pansiritanachot, MD

CONTACT

C

Chairat Permpikul, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here